Opinion|Videos|October 8, 2024
Overview of DAPA ECHO Trial
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- The DAPA ECHO trial focused on dapagliflozin's effects on myocardial performance in nondiabetic heart failure patients.
- A randomized, double-blind, placebo-controlled design was employed, using echocardiography to assess cardiac function.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 for the DAPA ECHO trial in which the effects of dapagliflozin on myocardial performance were studied in patients with nondiabetic heart failure.
- What was the objective of this analysis?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. What are the key clinical implications in using dapagliflozin in patients with nondiabetic heart failure?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
3
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
4
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
5